Biofrontera INC DEF 14A proxy statements

Biofrontera Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 11, 2026, to vote on director elections, an increase in equity plan shares, and auditor ratification.

Biofrontera Inc. is seeking stockholder approval for a reverse stock split to maintain Nasdaq listing and to enable full conversion and voting rights for recently issued Series C and Series D Preferred Stock.

Biofrontera Inc. has filed a supplement to its 2025 Annual Meeting proxy statement, clarifying that two key proposals, including an increase in authorized shares, are now considered routine matters by the NYSE, allowing brokers to vote uninstructed shares.

Biofrontera Inc. is holding its 2025 Annual Meeting of Stockholders virtually on June 12, 2025, to vote on key proposals including a share increase and director election.

Biofrontera Inc. is asking stockholders to approve an amendment to its 2021 Omnibus Incentive Plan to increase the number of shares available for issuance at the upcoming annual meeting on June 12, 2024.

Biofrontera Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on the election of directors and ratification of the company's auditor.

Biofrontera Inc. is holding a special meeting to seek stockholder approval for increasing its authorized common stock from 15 million to 35 million shares, primarily to fulfill obligations related to a recent private placement and for future business needs.